Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: Justification for direct measurement?

T. Sathyapalan, Stephen Atkin, E. S. Kilpatrick

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aim: The benefit of direct, as opposed to calculated, low density lipoprotein -cholesterol (LDL-C) measurement remains unclear. This study compared the biological variability of direct LDL in patients with type 2 diabetes (T2DM) on equivalent doses of the short half-life statin, simvastatin or the longer half-life statin, atorvastatin.Methods: A cross-over study of biological variation of lipids in 26 patients with T2DM taking either simvastatin 40 mg (n = 10) or atorvastatin 10 mg. After 3 months on one statin, fasting lipids were measured on 10 occasions over a 5-week period. The same procedure was then followed on the other statin. The variability of LDL-C was established using a Beckman direct assay.Results: As a group, mean LDL was no different between statins (mean ± s.d.) (1.69 ± 0.60 mmol/l simvastatin vs. 1.67 ± 0.60 mmol/l atorvastatin, p = 0.19). However, in all patients, the intraindividual biological variability of LDL while taking simvastatin was markedly higher than with atorvastatin (average s.d. = 0.17 mmol /l simvastatin vs. 0.01 mmol/l, p < 0.0001). Friedewald calculated LDL variability was no different between statins (average s.d. = 0.34 mmol /l simvastatin vs. 0.21 mmol/l atorvastatin, p = 0.19).Conclusions: In contrast to calculated values, direct measurement revealed LDL to be much more stable (the s.d. being an order of magnitude) in T2DM patients taking atorvastatin rather than simvastatin. This means LDL targets can be consistently met with less lipid monitoring using atorvastatin rather than simvastatin. Direct LDL measurement may therefore have a particular role in monitoring patients on statin treatment.

Original languageEnglish
Pages (from-to)540-544
Number of pages5
JournalDiabetes, Obesity and Metabolism
Volume12
Issue number6
DOIs
Publication statusPublished - Jun 2010
Externally publishedYes

Fingerprint

Simvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
LDL Cholesterol
Type 2 Diabetes Mellitus
Lipids
Half-Life
Atorvastatin Calcium
Physiologic Monitoring
Cross-Over Studies
oxidized low density lipoprotein
Fasting

Keywords

  • Direct LDL
  • Lipids
  • Statins
  • Variability

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{82158300d4a74075aef526ee4582c0c7,
title = "Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: Justification for direct measurement?",
abstract = "Aim: The benefit of direct, as opposed to calculated, low density lipoprotein -cholesterol (LDL-C) measurement remains unclear. This study compared the biological variability of direct LDL in patients with type 2 diabetes (T2DM) on equivalent doses of the short half-life statin, simvastatin or the longer half-life statin, atorvastatin.Methods: A cross-over study of biological variation of lipids in 26 patients with T2DM taking either simvastatin 40 mg (n = 10) or atorvastatin 10 mg. After 3 months on one statin, fasting lipids were measured on 10 occasions over a 5-week period. The same procedure was then followed on the other statin. The variability of LDL-C was established using a Beckman direct assay.Results: As a group, mean LDL was no different between statins (mean ± s.d.) (1.69 ± 0.60 mmol/l simvastatin vs. 1.67 ± 0.60 mmol/l atorvastatin, p = 0.19). However, in all patients, the intraindividual biological variability of LDL while taking simvastatin was markedly higher than with atorvastatin (average s.d. = 0.17 mmol /l simvastatin vs. 0.01 mmol/l, p < 0.0001). Friedewald calculated LDL variability was no different between statins (average s.d. = 0.34 mmol /l simvastatin vs. 0.21 mmol/l atorvastatin, p = 0.19).Conclusions: In contrast to calculated values, direct measurement revealed LDL to be much more stable (the s.d. being an order of magnitude) in T2DM patients taking atorvastatin rather than simvastatin. This means LDL targets can be consistently met with less lipid monitoring using atorvastatin rather than simvastatin. Direct LDL measurement may therefore have a particular role in monitoring patients on statin treatment.",
keywords = "Direct LDL, Lipids, Statins, Variability",
author = "T. Sathyapalan and Stephen Atkin and Kilpatrick, {E. S.}",
year = "2010",
month = "6",
doi = "10.1111/j.1463-1326.2009.01190.x",
language = "English",
volume = "12",
pages = "540--544",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin

T2 - Justification for direct measurement?

AU - Sathyapalan, T.

AU - Atkin, Stephen

AU - Kilpatrick, E. S.

PY - 2010/6

Y1 - 2010/6

N2 - Aim: The benefit of direct, as opposed to calculated, low density lipoprotein -cholesterol (LDL-C) measurement remains unclear. This study compared the biological variability of direct LDL in patients with type 2 diabetes (T2DM) on equivalent doses of the short half-life statin, simvastatin or the longer half-life statin, atorvastatin.Methods: A cross-over study of biological variation of lipids in 26 patients with T2DM taking either simvastatin 40 mg (n = 10) or atorvastatin 10 mg. After 3 months on one statin, fasting lipids were measured on 10 occasions over a 5-week period. The same procedure was then followed on the other statin. The variability of LDL-C was established using a Beckman direct assay.Results: As a group, mean LDL was no different between statins (mean ± s.d.) (1.69 ± 0.60 mmol/l simvastatin vs. 1.67 ± 0.60 mmol/l atorvastatin, p = 0.19). However, in all patients, the intraindividual biological variability of LDL while taking simvastatin was markedly higher than with atorvastatin (average s.d. = 0.17 mmol /l simvastatin vs. 0.01 mmol/l, p < 0.0001). Friedewald calculated LDL variability was no different between statins (average s.d. = 0.34 mmol /l simvastatin vs. 0.21 mmol/l atorvastatin, p = 0.19).Conclusions: In contrast to calculated values, direct measurement revealed LDL to be much more stable (the s.d. being an order of magnitude) in T2DM patients taking atorvastatin rather than simvastatin. This means LDL targets can be consistently met with less lipid monitoring using atorvastatin rather than simvastatin. Direct LDL measurement may therefore have a particular role in monitoring patients on statin treatment.

AB - Aim: The benefit of direct, as opposed to calculated, low density lipoprotein -cholesterol (LDL-C) measurement remains unclear. This study compared the biological variability of direct LDL in patients with type 2 diabetes (T2DM) on equivalent doses of the short half-life statin, simvastatin or the longer half-life statin, atorvastatin.Methods: A cross-over study of biological variation of lipids in 26 patients with T2DM taking either simvastatin 40 mg (n = 10) or atorvastatin 10 mg. After 3 months on one statin, fasting lipids were measured on 10 occasions over a 5-week period. The same procedure was then followed on the other statin. The variability of LDL-C was established using a Beckman direct assay.Results: As a group, mean LDL was no different between statins (mean ± s.d.) (1.69 ± 0.60 mmol/l simvastatin vs. 1.67 ± 0.60 mmol/l atorvastatin, p = 0.19). However, in all patients, the intraindividual biological variability of LDL while taking simvastatin was markedly higher than with atorvastatin (average s.d. = 0.17 mmol /l simvastatin vs. 0.01 mmol/l, p < 0.0001). Friedewald calculated LDL variability was no different between statins (average s.d. = 0.34 mmol /l simvastatin vs. 0.21 mmol/l atorvastatin, p = 0.19).Conclusions: In contrast to calculated values, direct measurement revealed LDL to be much more stable (the s.d. being an order of magnitude) in T2DM patients taking atorvastatin rather than simvastatin. This means LDL targets can be consistently met with less lipid monitoring using atorvastatin rather than simvastatin. Direct LDL measurement may therefore have a particular role in monitoring patients on statin treatment.

KW - Direct LDL

KW - Lipids

KW - Statins

KW - Variability

UR - http://www.scopus.com/inward/record.url?scp=77953184115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953184115&partnerID=8YFLogxK

U2 - 10.1111/j.1463-1326.2009.01190.x

DO - 10.1111/j.1463-1326.2009.01190.x

M3 - Article

C2 - 20518809

AN - SCOPUS:77953184115

VL - 12

SP - 540

EP - 544

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 6

ER -